Market Research Report
CRISPR Technology Market - Growth, Trends, and Forecast (2019 - 2024)
|Published by||Mordor Intelligence Pvt Ltd||Product code||911960|
|Published||Content info||114 Pages
Delivery time: 2-3 business days
|CRISPR Technology Market - Growth, Trends, and Forecast (2019 - 2024)|
|Published: September 1, 2019||Content info: 114 Pages||
Global CRISPR Technology market is expected to witness a CAGR of 24.3% during the forecast period. Certain factors that are driving the market growth include increasing government and private funding, rising demand, and adoption of CRISPR, technological advancements.
The rise in funding, initiatives by the government to develop vaccines, medical technologies, drugs, devices are further propelling the growth of the genome editing market globally. For instance, In May 2018, Feng Zhang's company Beam Therapeutics, a new startup to develop CRISPR, officially came out with USD 87 million in series. Funding and a mission to develop "precision genetic medicines" that use CRISPR technology to edit just one nucleotide base, or "letter," in the genome at a time. In 2018, Inscripta Colorado-based biotech acquired Solana Biosciences to ramp up the commercialization of its gene-editing technology. Aiming to broaden access to CRISPR by offering new enzymes for free, and to boost CRISPR research by outfitting scientists with a full suite of tools. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering.
CRISPR technology is a straightforward yet commanding tool for the purpose of editing genomes. It enables researchers to alter DNA sequences without difficulty and further modify gene function. It has a number of potential applications which include treating and preventing the spread of diseases, correcting genetic defects, and also, improving crops.
Biomedical is Expected to Hold Significant Market Share in the Application Segment
At present, the CRISPR (clustered regularly interspaced short palindromic repeat) restoration system is undeniably considered as one of the most suitable as well as promising options for genome editing. As compared to previous systems, CRISPR has more potentials and applications. Among all these, one important application is the use of CRISPR in understanding various genetic and epigenetic diseases including cancer. Study of cancer by the CRISPR system is mostly done by two approaches i.e. turning on the tumor suppressor genes and turning off the oncogenes. As per the exact capability of CRISPR, this system can also be utilized to create specific mutations in different cell lines in order to model the cancers. This type of modeling can result in a better understanding of a variety of diseases such as cancer and the ability to further develop effective drugs.
North America Dominates the Market and Expected to do Same in the Forecast Period
The region, especially the United States, has always been a pioneer in the field of genome editing, mostly due to the favorable government initiatives and increase in funding. The first-ever US trial of CRISPR in humans has begun in April 2019. Two patients are presently being treated as part of a study being conducted by the University of Pennsylvania. According to NPR (National Public Radio, America), both have certain forms of cancer which are difficult to treat and both have relapsed after standard treatments. As part of the trial, researchers are taking immune cells from the patients' bodies and then are editing them with CRISPR before again putting them back in. Such novel researches are expected to drive the overall market growth throughout the region.
The global CRISPR technology market is highly competitive and consists of a number of major players. Companies like Agilent Technologies, Cellecta, Inc., GeneCopoeia, Inc., GenScript, Horizon Discovery Group, Integrated DNA Technologies (IDT), Merck KGaA, New England Biolabs, Origene Technologies, Inc., Thermo Fisher Scientific, among others, hold the substantial market share in the CRISPR technology market.